propOFol
Trade name
Diprivan, Fresofol, Fresofol MCT-LCT, Propofol-Lipuro, Provive, Provive MCT-LCT
Presentation and preparation
Ampoule, bottle and vial:
10 mg/mL (volume: 20 mL, 50 mL, 100 mL)
Pre-filled syringe:
500 mg/50 mL
IV administration
Administration via a large vein or central line is recommended.
Shake well. Prepare the emulsion immediately before administration.
Give undiluted or dilute to 2 to 10 mg/mL and give as an injection over at least 20 to 30 seconds, or as an infusion, using an infusion pump with DERS.
Infusions: Non-PVC containers and giving sets should be used.
Undiluted infusions: Discard complete set (drug syringe and infusion line) after 12 hours.
Diluted infusions: Discard complete set (drug syringe and infusion line) after 6 hours.
RCH Standard Concentrations: 10 mg/mL
Other routes of administration
IM: Not recommended.
SC: Not recommended.
Compatible IV fluids
Glucose 5% (6 hours only)
Y-site only:
Sodium chloride 0.9%
Y-site only and Diprivan brand in glucose 5%:
Potassium chloride 20 mmol/L
Additional information
For use in theatre or intensive care settings only.
Patients who are allergic to eggs, peanuts and/or soybean products should not be given propofol.
Rapid administration may cause hypotension and apnoea.
Use only when facilities for cardiorespiratory monitoring and resuscitation exist.
Use with caution in patients with epilepsy, there may be a risk of seizures during the recovery phase.
Concomitant use of CNS depressants (e.g. opioids, parenteral benzodiazepines, IM olanzapine) increases the risk of respiratory depression, sedation, coma and death.
Taper the infusion slowly when discontinuing treatment; abrupt discontinuation may cause rapid awakening, anxiety, agitation and resistance to mechanical ventilation.
Solution should be a white or almost white oil in water emulsion (homogeneous).
Do not use if the emulsion has separated, appears to have precipitated or appears discoloured.
Discard any unused vial and bottle contents.
Protect from light during storage.